They have become a focus of recent research due to their important influence on the therapeutic benefits of modern clinical practice [45], as early HER2-positive breast cancer is always treated with a combination of chemotherapy and HER2 targeted therapy as well as hormonal therapy in hormonal positive cases. This evidence concerns the gene ERBB2 and breast cancer.